Rift Valley Fever Risk Map Model and Seroprevalence in Selected Wild Ungulates and Camels from Kenya by Britch, S.C. et al.
Rift Valley Fever Risk Map Model and Seroprevalence in
Selected Wild Ungulates and Camels from Kenya
Seth C. Britch1., Yatinder S. Binepal2., Mark G. Ruder3, Henry M. Kariithi2., Kenneth J. Linthicum1,
Assaf Anyamba4, Jennifer L. Small4, Compton J. Tucker4, Leonard O. Ateya2, Abuu A. Oriko2,
Stephen Gacheru5, William C. Wilson3*
1Center for Medical, Agricultural, and Veterinary Entomology, United States Department of Agriculture, Agricultural Research Service, Gainesville, Florida, United States of
America, 2 Biotechnology Center, Kenya Agricultural Research Institute, Nairobi, Kenya, 3Arthropod-Borne Animal Diseases Research Unit, Center for Grain and Animal
Health Research, United States Department of Agriculture, Agricultural Research Service, Manhattan, Kansas, United States of America, 4National Aeronautics and Space
Administration-Goddard Space Flight Center, Greenbelt, Maryland, United States of America, 5Director of Veterinary Services, Private Bag, Kabete, Kenya
Abstract
Since the first isolation of Rift Valley fever virus (RVFV) in the 1930s, there have been multiple epizootics and epidemics in
animals and humans in sub-Saharan Africa. Prospective climate-based models have recently been developed that flag areas
at risk of RVFV transmission in endemic regions based on key environmental indicators that precede Rift Valley fever (RVF)
epizootics and epidemics. Although the timing and locations of human case data from the 2006–2007 RVF outbreak in
Kenya have been compared to risk zones flagged by the model, seroprevalence of RVF antibodies in wildlife has not yet
been analyzed in light of temporal and spatial predictions of RVF activity. Primarily wild ungulate serum samples from
periods before, during, and after the 2006–2007 RVF epizootic were analyzed for the presence of RVFV IgM and/or IgG
antibody. Results show an increase in RVF seropositivity from samples collected in 2007 (31.8%), compared to antibody
prevalence observed from 2000–2006 (3.3%). After the epizootic, average RVF seropositivity diminished to 5% in samples
collected from 2008–2009. Overlaying maps of modeled RVF risk assessments with sampling locations indicated positive
RVF serology in several species of wild ungulate in or near areas flagged as being at risk for RVF. Our results establish the
need to continue and expand sero-surveillance of wildlife species Kenya and elsewhere in the Horn of Africa to further
calibrate and improve the RVF risk model, and better understand the dynamics of RVFV transmission.
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Introduction
The Rift Valley fever virus (RVFV) is an arbovirus of the genus
Phlebovirus of the family Bunyaviridae, and replicates in mosquitoes
and in vertebrates [1,2]. The virus causes Rift Valley fever (RVF),
an acute mosquito-borne zoonotic disease affecting animals and
humans [3]. The 12 kilobase viral genome consists of a single-
stranded, negative-sense tripartite RNA with ambisense polarity
[4–6]. The L, M, and S segments encode for the RNA-dependent
RNA polymerase (RdRp), envelope glycoproteins (Gn/Gc), and
nucleocapsid protein (N), respectively [7]. In domestic ruminants,
RVF causes high mortality in young animals and sudden onset of
abortions in pregnant animals. In humans, uncomplicated RVF
cases may present as an acute febrile illness, although more serious
complications do occur (ranging from fatal hemorrhagic disease,
meningoencephalitis, renal failure, and blindness) [8–11] and in
some cases death (human case-fatality rate of approximately 0.2 to
5%) [12].
Since the first isolation of the virus in the 1930s there have been
multiple epizootics and epidemics in sub-Saharan Africa [13–16],
in southern and eastern Africa [17], Sahel, West Africa, and in
Egypt in 1977 and 1978 [18]. RVFV was thought to be restricted
to Africa; however, during 2000 the disease was reported in
Yemen and Saudi Arabia [19] but appears not to have become
established [20,21]. RVFV has potential for further international
spread due to many factors including climatic changes, human-
induced environmental modification (e.g., irrigation, dams, or
urbanization), or increases in transportation networks or animal
agriculture and trade [22,23]. The RVF epizootics occur at
irregular intervals of 3–15 years, mainly after heavy rains that
flood natural depressions in the grasslands of sub-Saharan Africa
[24]. The flooding allows hatching of multiple species of Aedes
mosquitoes, the primary vectors/reservoirs, which eventually feed
on nearby vertebrate animals thereby transmitting the virus
[25,26]. The recent RVF epizootic and epidemic in East Africa
from 2006–2007 demonstrated that sustained flooding in several
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parts of the country could have a significant impact on livestock
and human health [27–29]. In addition, reports have shown that
clusters of high RVF seroprevalence encompass areas that
experienced previous disease epidemics [30]. The significant role
of mosquitoes in RVFV transmission has resulted in the
generation of climate-based models to predict the risk of RVF
outbreaks within endemic areas in Africa using a combination of
temporal and spatial historical records of RVF activity and
remotely sensed satellite environmental data, including vegetation
indices, sea surface temperatures, and proxy indicators of rainfall,
that directly affect RVFV vector mosquito development and
survival in RVF-endemic regions [22,31,32].
Rift Valley fever infection in humans can be acquired through
mosquito bites; however, the primary risk factors are contact with
infected domestic animals or animal parts, or consumption of raw
meat, blood, or milk [33–36]. We have previously shown that
human RVF cases are observed in or near zones of elevated risk
for RVFV transmission flagged by the climate-based predictive
model [31,32]. This is likely associated with an increased risk of
RVFV infection of livestock or wild animals due to development of
favorable habitat for mosquito vectors. We have previously
demonstrated a relationship between herd management and
RVF seroprevalence. Free ranging livestock that may have been
removed from or intermittently exposed to mosquito vectors of
RVFV were found to have a lower seroprevalence than sedentary
livestock herds in high risk areas that may have been subject to
persistent exposure to infectious mosquitoes [37]. However, the
relationship of RVF seroprevalence in either wild or domestic
animals with RVF risk models has not been examined.
There is a need to better understand the potential role of wild
mammals in the epidemiology of RVF, especially in regard to the
potential inter-epizootic transmission and maintenance of RVFV
in enzootic regions [38]. A limited number of studies have
examined the prevalence of RVFV antibodies in a range of
African wildlife species and similar to this study, most have focused
on ungulate species in the orders Artiodactyla and Perissodactyla.
For instance, free-ranging black rhinos, African buffalo, and
waterbuck in Zimbabwe have been shown to have antibodies to
RVFV [39], white rhinos were found to have a high seropreva-
lence for RVFV antibodies in Kruger National Park, South Africa
[18], and RVFV antibodies have been detected in low frequencies
in African buffalo sampled from Kenya and South Africa [40,41].
A serological survey found neutralizing antibodies against RVFV
in Kenyan wildlife born during the inter-epidemic period
preceding the 2006–2007 outbreak, including African buffalo,
black rhino, lesser kudu, impala, African elephant, kongoni (i.e.,
hartebeest), and waterbuck [42]. However, a much higher
seroprevalence was found in wild ruminants, including gerenuk,
waterbuck, and eland, in samples collected during the 2006–2007
epizootic and epidemic [42]. Although the potential role of
domestic and wild mammals in RVFV maintenance during inter-
epidemic periods is not fully understood [27], these studies suggest
that surveys of wild animal serology could potentially be leveraged
as early indicators of RVFV activity to augment early indicators
based on rainfall and vegetation development in models of RVFV
transmission risk. Here we describe a retrospective and opportu-
nistic RVF serosurvey of Kenyan wild ungulates from the Order
Artiodactyla. The primary objective was to examine temporal and
spatial variation in RVF seroprevalence in sampled Kenyan wild
ungulates and determine if a preliminary relationship between
predicted RVF risk and wildlife seroprevalence could be demon-
strated.
Materials and Methods
Sera
A total of 840 (wild ungulate (n = 784) and camel (n = 56)) serum
samples from 15 Kenya locations (Fig. 1) were obtained from the
Veterinary Laboratories in Kabete, Kenya. These samples were
collected between 2000 and 2009 for disease surveillance
(especially PPR and Rinderpest) not directly related to this
project, but provide an unbiased sample collection with regard to
temporal and spatial continuity. These serum samples span the
pre-epizootic, epizootic, and post-epizootic periods and regions of
the 2006–2007 RVF outbreak in Kenya and are a unique resource
to preliminarily examine possible alignment of RVF risk predic-
tions and observed RVF activity. Of these, 183 samples had been
collected over a period of seven years (2000–2006) preceding the
outbreak from 6 locations, 299 samples had been collected in 2007
during the outbreak from 5 locations, and 358 samples had been
collected in 2008–2009 after the outbreak from 8 locations
(Table 1). The serum samples were coded (location, species, date,
and animal number) and stored in aliquots at280uC. The age and
health status of the sampled animals are not known. Precise
geolocations of samples were not recorded during sampling;
therefore locations were estimated using location names associated
with each sample. Seven of the 15 locations, Lake Naivasha,
Marsabit, Meru, Lake Nakuru, Maasai, Tsavo East, and Amboseli
are well-known conservation areas in Kenya and geolocation for
samples collected from these areas was estimated as centroid or the
urban center of the conservation area boundary polygon (Fig. 1).
For the remaining 8 locations, Mandera, Wajir, Laikipia, Isiolo,
Garissa, Ijara, Tana Delta, and Galana were taken as the point
location of the urban centers for the samples with these names
(Fig. 1). In cases where samples had similar, but not identical
location names, for example Marsabit and Marsabit Lodge
(Table 1) or Nakuru and Lake Nakuru (Table 1), these samples
were grouped into a single location, for example ‘‘Marsabit’’ or
‘‘Nakuru’’, for mapping purposes (Fig. 1).
The samples used in this study were diagnostic specimens sent
to the Kenya Department of Veterinary Services, Veterinary
Laboratory in Kabete, Kenya. These samples were taken by the
Kenyan Wildlife Services staff according to their national
standards. The authors conducted no animal handling or
sampling. Samples were used with permission from the Kenyan
Department of Veterinary Services and Wildlife Services.
Inhibition ELISA Test
The procedure for inhibition ELISA that detects both IgG and
IgM used in this study was based on a previously described
method [43]. Briefly, polystyrene ELISA microtitre plates
(MaxiSorp, NuncTM, Denmark) were coated with 100 ml per well
with polyclonal sheep anti-RVFV capture antibody in 0.01 M
phosphate buffered saline (PBS), pH 7.4, overnight in a humidity
chamber at 4uC. The plates were washed four times with PBS/
0.05% Tween-20; the same washing step was performed for all
subsequent washing steps. Plates were blocked with 10% non-fat
milk/PBS (1 h; 37uC). During the blocking stage, undiluted test
and control sera were each added into diluting wells containing
virus or control antigen pre-diluted in 2% skim milk in PBS. Test
and control sera/virus antigen mixture was added to rows A–D 1–
12 and test and control sera/control antigen mixture to rows E–H
1–12 and incubated for 1 h in a moist chamber at 37uC. The
plates were then washed, followed incubation with mouse anti-
RVFV antibodies (1 h; 37uC). After washing, the plates were
incubated with anti-mouse IgG HRPO-conjugate diluted 1:2000
(1 h; 37uC). The plates were washed six times as before, and
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Figure 1. Map of Kenya showing 2000–2009 serology sample locations and relevant Kenya conservation areas.
doi:10.1371/journal.pone.0066626.g001
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Table 1. Wildlife sera collected in different locations during pre-epizootic, epizootic, and post epizootic RVF outbreak in Kenya.
Sampling period Area Species Date of collection
Total samples
collected Positive samples % Positive samples
2000–2006 (pre-
epizootic) period
Tsavo buffalo 11/10/2000 10 0 0
Maasai Mara buffalo 14/10/2000 2 0 0
Galana camel 14/10/2000 15 1 6.7
Garissa camel 10/11/2000 13 1 7.7
Laikipia buffalo 28/7/2004 49 0 0
Amboseli National Park eland 26/11/2006 15 0 0
giraffe 26/11/2006 16 0 0
waterbuck 26/11/2006 17 2 11.8
buffalo 26/11/2006 21 1 4.8
kongoni 26/11/2006 14 0 0
gazelle 26/11/2006 11 1 9.1
Total 183 6 3.3%
2007 epizootic
period
Lake Naivasha National
Park
buffalo 6/1/2007 27 11 40.7
Laikipia waterbuck 2/1/2007 2 0 0
eland 23/1/2007 3 0 0
giraffe 23/1/2007 8 0 0
buffalo 23/1/2007 111 9 8.1
Nakuru waterbuck 2/2/2007 4 1 25
warthog 2/2/2007 1 0 0
Lake Nakuru gazelle 2/2/2007 26 0 0
Maasai Mara waterbuck 2/2/2007 1 0 0
gazelle 2/2/2007 1 0 0
buffalo 2/2/2007 25 15 60
eland 2/2/2007 1 1 100
giraffe 2/2/2007 7 2 28.6
gerenuk 2/2/2007 6 4 66.7
warthog 2/2/2007 42 32 76.1
Lake Naivasha National
Park
impala 2/6/2007 2 2 100
waterbuck 3/6/2007 4 2 50
Isiolo Webera camel 28/6/2007 28 16 57.1
Total 299 95 31.8%
2008–2009 (post-
epizootic) period
Wajir warthog 18/2/2008 11 1 9.1
Marsabit warthog 18/2/2008 2 0 0
Mandera warthog 18/2/2008 12 0 0
Wajir giraffe 8/9/2008 10 0 0
Marsabit Lodge giraffe 8/9/2008 2 0 0
Mandera East giraffe 8/9/2008 2 0 0
Wajir warthog 8/9/2008 8 0 0
Ijara (Kotile) warthog 8/11/2008 7 0 0
SBT Klegdela warthog 11/11/2008 22 1 4.6
Marsabit buffalo 11/11/2008 2 0 0
Meru Conservation Area buffalo 11/11/2008 61 1 1.6
Tana Delta buffalo 11/11/2008 40 2 5
Meru Conservation Area waterbuck 11/11/2008 6 1 16.7
Tsavo East giraffe 27/11/2008 5 0 0
lesser kudu 27/11/2008 2 0 0
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developed by addition of 2,29-azino-bis(3-ethylbenthiazoline-6-
sulphonic acid) (ABTS) substrate. Optical densities (O.D) were
then measured in a Multiskan EXR plate reader (Thermo Electron
Corp.) using a 405 nm filter.
Serology Scoring
The specific activity of each serum (net optical density, O.D.)
was calculated by subtracting the non-specific background OD in
the wells with control antigen from the specific O.D. in wells with
virus antigen. The mean OD readings for replicate tests were
converted to a percentage inhibition (PI) value. Sera that gave
more than 34.2% inhibition (O.D. neg.24.266s.d., P=0.001;
where s.d. = 0.05) were scored as seropositive for RVFV antibod-
ies.
RVF Risk Maps
The methods for producing RVF risk maps have been described
in detail elsewhere [22,31,32,44] and are only summarized here.
Prospective risk analysis for RVF activity is triggered by changes in
global climate patterns indicated by sea surface temperatures and
the El Nin˜o/Southern Oscillation phenomenon that predict high
likelihood of prolonged and above-normal rainfall in RVF-
endemic regions of Africa and the Arabian Peninsula within 2 to
5 months [17,22,31–33]. In most RVF-endemic regions, excess
and prolonged rainfall has a positive linear relationship with
vegetation development [45–47]. Photosynthetic activity resulting
from vegetation development produces characteristic reflections of
solar radiation that are routinely recorded by satellite instruments
and used to calculate the normalized difference vegetation index
(NDVI) [48,49]. The ‘‘greening’’ of habitat indicated by increases
in NDVI in turn has a direct relationship with RVFV mosquito
vector development, emergence, and survival [45]. Specifically, 3
months of sustained excess rainfall and resultant persistent
increases in NDVI are strongly indicative of impending high
levels of RVFV transmission in large part due to extremely
favorable vector mosquito habitat [16,45].
The boundaries of the risk maps are set by creating a spatial
mask that defines the potential epizootic area (PEAM)
[16,31,32,44]. This mask is derived by a thresholding method
on NDVI climatological values that range between 0.15–0.4
NDVI units. A map derived from the thresholding method
identifies the savanna complexes of Africa, which are subject to
extremes in interannual climate variability. The mask includes
those areas that receive between 200–800 mm/yr of rainfall.
These are primarily the regions where RVF outbreaks have been
described, especially in East Africa, Southern Africa, and the Sahel
region [50]. Thus, the spatial boundaries of the model are set to
include mainly areas that possess the environmental infrastructure
for RVFV vector development and host domestic animals. The
PEAM is shown in green color on RVF risk map figures and
designated the ‘‘Potential Epizootic Region.’’ Areas outside the
PEAM include areas that may not possess obvious appropriate
habitat but some may have nevertheless experienced RVFV
transmission. Within the regions highlighted by the PEAM, the
risk model flags 1 km2 blocks that show 3 month persistence in
above-normal NDVI data from SPOT-Vegetation optical instru-
ments on board SPOT-4 and -5 satellites as RVF risk areas.
Above-normal NDVI is derived by comparing the percentage
departure of current month NDVI values against 10-year mean
NDVI values for that month in a 3-month moving window. Maps
are output from the model on a monthly basis showing the RVF
potential epizootic area and flagged RVF risk areas. As patterns of
rainfall and vegetation development unfold over time, areas at risk
of RVF may emerge or fade with these changing conditions as the
monthly risk estimates are produced.
To match the temporal framework of the serological samples we
extracted mapped RVF risk assessments for the month samples
were collected as well as the preceding month, given that
antibodies detected in a month could have been the result of
exposure in a prior month. Estimated serology sample locations for
each sample month were then mapped with the RVF risk
assessments, and we examined each sample month and prior
month for spatial co-occurrence of seropositivity and predicted
RVF risk.
Results
The 840 serum samples analyzed in this study were collected
from four families within the order Artiodactyla. Wild ungulate
species tested include African buffalo (Syncerus caffer, n = 437),
warthog (Phacochoerus africanus, n = 139), waterbuck (Kobus ellipsipry-
mus, n = 41), giraffe (Giraffa camelopardalis, n = 79), gazelle (Gazella
sp., n = 38), common eland (Tragelaphus oryx, n = 22), kongoni or
hartebeest (Alcelaphus buselaphus, n = 14), gerenuk (Litocranius walleri,
n = 10), impala (Aepyceros melampus, n = 2), and lesser kudu
(Tragelaphus imberbis, n = 2). Although a domesticated species,
samples from dromedary camels (Camelus dromedarius, n = 56) were
also included in this study. The sampling sites consisted of 7
Table 1. Cont.
Sampling period Area Species Date of collection
Total samples
collected Positive samples % Positive samples
Meru Conservation Area eland 27/11/2008 3 0 0
Meru Conservation Area warthog 27/11/2008 4 1 25
Ijara (Hare) warthog 27/11/2008 30 0 0
Tsavo East buffalo 27/11/2008 89 9 10.1
waterbuck 27/11/2008 7 1 14.3
Wajir gerenuk 17/2/2009 2 0 0
Meru Conservation Area giraffe 18/2/2009 29 1 3.5
Ijara (Hulugho) gerenuk 18/2/2009 2 0 0
Total 358 18 5%
The results of the analysis of the RVFV antibodies in the samples by recombinant N inhibition ELISA are indicated.
doi:10.1371/journal.pone.0066626.t001
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conservation areas, such as national parks and game reserves, and
8 rural regions in Kenya (Fig. 1). Year-to-year patterns of change
in percent seropositive samples by species and by locations are
shown in Figs. 2 and 3, respectively. Specific seropositive
percentages by sample site per species by sample month and year
are shown as pie charts with relevant maps of RVF risk
assessments (Figs. 4–6).
The total number of wildlife serum samples analyzed for
presence of RVFV antibodies during the pre-epizootic (2000–
2006), epizootic (2007), and post-epizootic (2008–2009) periods
are indicated in Table 1. Although the RVF outbreak studied here
is recorded as a 2006–2007 outbreak, the samples taken in
November, 2006, are grouped as pre-epizootic samples because (a)
the November, 2006, rate of seropositivity more closely matches
rates in the earlier 2000–2006 pre-epizootic samples, (b) the RVF
risk assessments for October and November, 2006, were low in
southern Kenya and more indicative of pre-epizootic conditions
and (c) the outbreak began in December 2006.
Approximately 5% (n= 40) of the samples collected in 2000 and
4.3% (n= 94) of the 2006 samples were found to be positive for
RVFV antibodies by the inhibition ELISA test, while 0% (n= 49)
of the samples collected in 2004 were positive (Table 1).
Serologically positive samples in the 2000–2006 pre-epizootic
period were detected in camel (7.2%, n= 28), waterbuck (11.8%,
n= 17), buffalo (1.2%, n= 82), and gazelle (9.1%, n= 11). It is
noteworthy that none of the giraffe (n = 16), common eland
(n = 15), or kongoni (n = 14) samples were seropositive for RVFV
during the pre-epizootic period (Table 1, Figs. 2–3).
In contrast to pre-epizootic samples, 31.8% (n= 299) of the
2007 samples taken during the RVF epizootic were found to be
positive. For the 2007 epizootic period, serologically positive
samples were detected in camel (57.1%, n= 28), waterbuck
(27.3%, n= 11), impala (100%, n= 2), buffalo (21.5%, n= 163),
common eland (25%, n= 4), giraffe (13.3%, n= 15), gerenuk
(66.7%, n= 6), and warthog (74.4%, n= 43). Interestingly, 2 of 2
(100%) samples collected from impala at Lake Naivasha National
Park were positive and the one (100%) common eland sample
collected from Maasai Mara National Park was also positive,
although these results should be interpreted with caution due to
very small sample sizes. Higher percentages of RVFV seroposi-
tivity were detected from gerenuk (66.7%, n= 6), warthog (76.2%,
n= 42), buffalo (60%, n= 25), and giraffe (28.6%, n= 7) sampled
specifically from Maasai Mara National Park. The RVF
seroprevalence during the epizootic were from domestic camel
(57.1%, n= 28) sampled from Isiolo Webera and waterbuck (50%,
n= 4) and buffalo (40.7%, n= 27) sampled from Lake Naivasha
National Park. No RVFV antibody was detected in gazelle during
the epizootic period (Table 1, Figs. 2–3).
From the samples of wildlife sera analyzed from the 2008–2009
post-epizootic period, there was a reduction in RVFV seropositive
samples detected by inhibition ELISA. Of the 325 serum samples
analyzed from 2008, only 5.2% were positive for RVFV
antibodies, and of the 33 samples analyzed from 2009, only 3%
were seropositive. The majority of seropositive samples detected in
2008–2009 were from giraffe (2.1%, n= 48), warthog (3.1%,
n= 96), buffalo (6.3%, n= 192), and waterbuck (15.4%, n= 13).
The highest single-location RVF seroprevalence result for the
2008–2009 post-epizootic period were detected in warthog (25%,
n= 3) and waterbuck (16.7%, n= 6) from the Meru Conservation
Area, and waterbuck (14.3%, n= 7) from Tsavo East National
Park. The remaining samples from 2008–2009 were generally less
than 10% seropositive. No positive sample was detected from
Figure 2. Bar graphs showing by-species patterns of change in RVFV seropositivity before, during, and after the 2006–2007 RVF
epizootic.
doi:10.1371/journal.pone.0066626.g002
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samples collected from lesser kudu (n= 2), gerenuk (n = 4), or
common eland (n= 3) in the post-epizootic period (Table 1,
Figs. 2–3).
Relevant monthly outputs from the RVF risk assessment model
are mapped in Fig. 4 (pre-epizootic period), Fig. 5 (epizootic
period), and Fig. 6 (post-epizootic period). The key observations
across Figs. 4–6 are whether locations with serology values .0 for
any sampled ungulate species co-occur with map pixels flagged for
risk of RVFV transmission. Although pixels flagged for RVFV
transmission risk may not be at or directly adjacent to plotted
sample locations, we may consider risk-flagged pixels within an
arbitrary radius of 75 km from each location – not only because all
plotted locations are only estimates of the actual sample locations,
which were not recorded with the serosamples, but also because
the animals range freely and may not have become exposed to
RVFV where they were sampled. In some months shown in
Figs. 4–6, the density of risk pixels is very low across the landscape,
and in other months the density is high. For each location we ran a
GIS analysis that counted the number of flagged pixels in a 75 km
radius and the area at risk for each sample month. Results shown
in Table 2 support the direct observation that in the pre-epizootic
and post-epizootic periods, the density of risk pixels was lower, and
the frequencies of seropositive samples were lower, than during the
epizootic period.
Both pre- and post-epizootic sample locations were in areas that
had been exposed to risk of RVFV transmission during the
epizootic period, as estimated by the risk model. Sample locations
from during the epizootic were in areas not flagged as at-risk
during the pre- and post-epizootic periods. Thus, despite the lack
of contiguous longitudinal spatial/temporal serum samples, the
appraised space as a whole may provide insight into the alignment
of predictions of RVF activity and observed dynamics of
seroprevalence.
Discussion
The current study was conducted to compare spatial and
temporal patterns of available RVF seropositivity data in wild
ungulates and camels to zones and timing of potential elevated
RVFV transmission predicted by a RVF risk mapping model
before, during, and after the 2006–2007 RVF epizootic and
epidemic in Kenya. The availability of this unique set of wild
ungulate serology data that fortuitously coincided with the location
and timing of a major RVF epizootic and epidemic permits two
independent ways to look at the outbreak, one through
Figure 3. Bar graphs showing by-location patterns of change in RVFV seropositivity before, during, and after the 2006–2007 RVF
epizootic.
doi:10.1371/journal.pone.0066626.g003
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Figure 4. Monthly predicted RVF risk assessment map overlaid with serological results collected prior to the 2006–2007 RVF
outbreak; A) Tsavo East in September and October 2000, B) Garissa in October and November 2000, C) Laikipia in June and July
2000, and D) Amboseli in October and November 2000. The light green background color shows the extent of the potential epizootic region
and high risk is indicated by red color in 1 km2 pixels. Magenta lines represent polygons for conservation areas such as national parks or preserves.
For each sample month, the left-hand map shows the RVF risk conditions for the prior month, and the right-hand map shows the month the samples
were taken, along with sample locations. Below the maps for sample months, pie charts show the proportion of samples found to be RVF
seropositive for each species, by location. Only locations sampled in that month are plotted.
doi:10.1371/journal.pone.0066626.g004
Figure 5. Monthly predicted RVF risk assessment map overlaid with serological results collected during the 2006–2007 RVF
outbreak; A) Laikipia and Naivasha in December and January 2006, B) Maasai and Nakuru in January and February 2007, and C)
Isiolo and Naivasha in May and Jun 2007. See Fig. 4 for descriptive legend.
doi:10.1371/journal.pone.0066626.g005
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environmentally- and case-based modeling, and one through a
landscape-level survey of the indications of infection in wild
ungulates. Considering the serology as a single group, even given
the limitations of the data (we do not know the animal’s age, exact
location, or its full home range), we observe that in inter-epizootic
periods, RVF seroprevalence in the wild ungulates sampled is low;
during epizootics it is higher. In addition, the study is limited to
seroprevalence based on inhibition ELISA results that can vary
from the more definitive virus neutralization (VN) assay that
requires high biosecurity to perform. Ideally, VN assays would be
performed to confirm ELISA-positive samples but unfortunately,
the sera collection was damaged due to equipment failure before
arrangements could be made. This preliminary appraisal, howev-
er, suggests that during RVF outbreaks in domestic animals and
humans, we observe that some wild ungulate species also show
signs of having been infected. At the landscape level, wild ungulate
serology results were generally associated with the predicted
patterns of RVFV transmission. Outbreaks of RVF in human
populations are generally preceded by epizootics in livestock and it
was previously demonstrated that human and livestock RVF cases
clustered during this 2006–2007 outbreak in Kenya [28].
Identification of wildlife hosts that may be involved in the
epidemiology of RVF, during both inter-epizootic and epizootic
periods, is important to not only furthering our understanding of
the ecology of this disease, but also in potentially informing and
improving the climate-based RVF risk model.
Ungulate samples collected from 2000–2006 had a low
seroprevalence, corresponding to the inter-epizootic period when
Figure 6. Monthly predicted RVF risk assessment map overlaid with serological results collected after the 2006–2007 RVF outbreak;
A) Marsabit, Mandera, and Wajir in January and February 2008, B) Marsabit, Mandera, and Wajir in August and September 2008, C)
Ijara, Klegdela, Marsabit, Meru, Tana, and Tsavo in October and November 2008. See Fig. 4 for descriptive legend.
doi:10.1371/journal.pone.0066626.g006
Table 2. RVF risk quantified in a 75 km radius from each sample location.
AREA OF RVF RISK (km2 in 75 km
radius)
% AREA OF RVF RISK (km2 risk/
17,671 km2)
Period Year Month Area % Seropositive
(month before
sample)
(month of
sample)
(month before
sample) (month of sample)
Pre- 2000 OCT Galana 6.7 13 85 0.1 0.5
Epizootic Maasai 0 0 0 0 0
Tsavo 0 0 2 0 0
NOV Garissa 7.7 2 2 0 0
2004 JUL Laikipia 0 1,324 58 7.5 0.3
2006 NOV Amboseli 4.3 157 285 0.9 1.6
Totals, Pre-Epizootic: 3.3% 1,496 432 – –
Epizootic 2007 JAN Naivasha 40.7 173 2,017 1.0 11.4
Laikipia 7.3 1,067 7,941 6.0 44.9
FEB Maasai 65.1 510 4,020 2.9 22.7
Nakuru 3.2 1,501 4,216 8.5 23.9
JUN Naivasha 66.7 842 1,790 4.8 10.1
Isiolo 57.1 87 167 0.5 0.9
Totals, Epizootic: 31.8% 4,180 20,151 – –
Post- 2008 FEB Marsabit 0 146 85 0.8 0.5
Epizootic Wajir 9.1 22 0 0.1 0
Mandera 0 1 0 0 0
SEP Marsabit 0 0 0 0 0
Wajir 0 24 0 0.1 0
Mandera 0 0 1 0 0
NOV Marsabit 0 135 2,602 0.8 14.7
Meru 4.1 1,234 2,275 7.0 12.9
Tsavo 9.9 0 26 0 0.1
Tana 5 105 74 0.6 0.4
Ijara 0 73 135 0.4 0.8
2009 FEB Meru 3.5 555 363 3.1 2.1
Wajir 0 1,200 62 6.8 0.4
Ijara 0 542 166 3.1 0.9
Totals, Post-Epizootic: 5% 4,037 5,789 – –
doi:10.1371/journal.pone.0066626.t002
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predicted risks were low. Interestingly, in addition to waterbuck
and buffaloes, domesticated camels were among the seropositive
samples during this timeframe. Camels were heavily impacted in
the 2010 RVF outbreak in a non-endemic area of Mauritania [51]
and could be among livestock species that could function as
particularly sensitive indicators of RVF activity, perhaps because
of their longevity and specific range of movement. During the
2000–2006 pre-epizootic period, 7.1% (2/28) of domestic camel
samples tested positive, which increased to 57.1% (16/28) testing
positive during the 2007 epizootic sampling period (Fig. 2). As the
predicted zones of RVF risk in Kenya increased from October
2006, until March 2007, the proportion of positive serum samples
similarly increased.
In the years following the 2006–2007 RVF outbreak, predicted
risk remained low, as did the seroprevalence of RVFV antibodies
in wild ungulate sera collected in 2008–2009. However, the sharp
reduction in seroprevalence observed during the post-epizootic
period should be interpreted with caution, as it may be an artifact
of sampling. On the one hand, some degree of herd immunity
would be expected to persist following widespread exposure to the
virus; however, the age structure across the samples was not
recorded, and these later samples could have been biased towards
younger animals born in the months following the 2006–2007
epizootic. Furthermore, the intensity of sampling efforts at each
location and with each species varied between 2007 epizootic and
2008–2009 post-epizootic periods. Indeed, the samples available
for this study were very limited and collected for reasons not
directly related to the study. These factors may help explain the
marked decrease in RVF seroprevalence observed during 2008/
2009 in some locations. However, our findings do suggest a
general alignment between predictions of increasing risk and wild
ungulate and camel RVF seroprevalence. For example, results
indicate increases in exposure to RVFV inferred from the total
population of samples collected in 2007 (31.8%, n= 299),
compared to exposure inferred from the total population of
samples collected in 2006 (4.3%, n= 94). After the outbreak, there
was a reduction in inferred RVFV exposure in the total population
of samples from 2008–2009 (5%, n= 358).
During the 2007 epizootic period, we found a large proportion
($25%) of African buffalo, common eland, giraffe, gerenuk,
warthog, impala, and waterbuck sampled at single locations to be
seropositive, although sample size was low for some species. A
previous serosurvey in Kenya demonstrated that African buffalo,
lesser kudu, Thomson’s gazelle, impala, black rhino, and
waterbuck sampled during this same outbreak had a relatively
high prevalence ($15%) of neutralizing antibodies against RVFV
[42]. Interestingly, that study also suggested that giraffe and
warthogs may not be permissive to RVFV replication or that they
are not the preferred host of competent vectors based on the low
number of seropositive samples. However, the 76.2% (32/42) and
28.6% (2/7) ELISA-positive warthog and giraffe samples, respec-
tively, observed during our study suggest otherwise and indicates
how little we know regarding the potential wild ungulate host
range.
For each of these four species (African buffalo, common eland,
giraffe, and waterbuck) sampled before, during, and after the
epizootic, the proportion of positive ELISA results was greater in
2007 samples than in samples from any other year. For instance,
seroprevalence in buffalo was zero (0/61) in 2000–2004 samples,
slightly increased to 4.8% (1/21) in 2006, and then increased to
21.5% (35/163) in 2007 but was as high as 60% (15/25) in Maasai
Mara, followed by a decrease back to 10% or less in 2008 samples.
Similar patterns are seen in RVF seroprevalence rates in giraffe
and common eland in the years during and adjacent to the
epizootic period – yet only the buffalo samples can be compared
across years at a single location. Less dramatic shifts in
seroprevalence were observed in waterbuck, a grassland-woodland
species that generally remains within a few miles of water sources:
16.7% (2/12), 30% (3/10), and 15.4% (2/13) for pre-epizootic,
epizootic, and post-epizootic periods, respectively.
Although variable, an increase in RVF seroprevalence rates
between pre-epizootic and epizootic periods was observed in
camels and in wild ungulate species, including African buffalo,
common eland, giraffe, and waterbuck. Although not included in
the pre-epizootic sampling period, impala, gerenuk, and warthog
all displayed high seropositivity in 2007 samples, and all but
impala have samples from the post-epizootic period that demon-
strate lower RVF seroprevalence. The above-mentioned species
may all represent potential indicators of RVFV activity that future
serological studies may include. Gazelle showed some signs of
exposure (9.1%, 1/11) to RVFV in Amboseli in late 2006 when
RVF risk was beginning to emerge throughout Kenya, but large
gazelle samples taken during the peak of the epizootic from
epicenters of risk curiously showed no signs of exposure (0%, 0/
27). However, this finding should be interpreted with caution. In
another study, 87.5% (7/8) of Thomson’s gazelle sampled from
Kenya during the 1999–2005 inter-epizootic period tested positive
for neutralizing antibodies to RVFV [42].
It is noteworthy that three grassland ungulate species that
frequently occupy woodland-grassland edge habitat and do not
range far from water sources were all found to be seropositive
during the study, these include African buffalo, waterbuck, and
impala. Only two impala were sampled, but both tested positive
during the 2007 epizootic. Some proportion of serum samples
collected from African buffalo (n = 437) and waterbuck (n= 41)
during each of the three sampling periods (pre-epizootic, epizootic,
and post-epizootic) were positive, suggesting exposure during
inter-epizootic periods. These species may be good candidates to
include in future longitudinal surveys of wild mammals in
ecological zones where RVF may display a more enzootic pattern.
However, so little is known regarding natural enzootic and
epizootic cycles of RVF in wild mammals, that broader surveys
encompassing species from a variety of mammalian taxonomic
orders are indicated.
Although the overall percentages of positive serology provide
encouraging evidence of linkage between serology and periods of
predicted RVFV transmission risk, there are limitations to the
conclusions we can make from this opportunistic data set.
Limitations include 1) the relatively limited species diversity in
the serum samples analyzed, 2) temporal discontinuity of the
species sampled, and 3) discontinuity of the geographic locations
sampled over time. The first limiting condition is that the majority
(78%, 655/840) of samples analyzed were from three species:
African buffalo, warthog, and giraffe, with African buffalo
comprising 52% (437/840) of the dataset. Seven other wild
ungulate species and domestic camels accounted for the remaining
22% (185/840) of serum samples. Another limiting factor was the
temporal discontinuity of species sampled (Fig. 2). Of the 11
species sampled across the entire study period, only 4 species,
buffalo, eland, giraffe, and waterbuck, have samples from before,
during, and after the epizootic. The third limiting condition to
conclusions of risk-serology linkage is the non-continuity of
locations sampled (Fig. 3). Laikipia and Maasai are the only
locations with pre-epizootic samples that may be compared to
samples taken during the epizootic, and at both locations buffalo is
the only species with samples from both periods and no samples in
post-epizootic years for any species. Tsavo East has samples from
before and after the epizootic, but not during the epizootic;
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however, buffalo were sampled in these periods and show 10%
positive serology following the epizootic compared to 0% from the
pre-epizootic period. No location was sampled in all three periods,
but of the 5 locations sampled in 2007 during the epizootic, Isiolo,
Maasai Mara, and Lake Naivasha, each showed around 60%
seroprevalence across all samples. Data are not available from the
epizootic for the majority of locations in this study, yet high RVF
seroprevalence indicates that these locations should be among the
first to be examined in future, rigorous longitudinal sero-surveys.
Recognizing these limitations, the current study retrospectively
supports not only mid-2006 predictions of the 2006–2007 RVF
outbreak as published by Anyamba et al. [52], but also furthers
our understanding of the apparent epidemiological sequence of
RVFV transmission on which the RVF predictive model is based.
Global climate anomaly monitoring processed through the RVF
predictive model triggered alerts anticipating substantial RVFV
transmission from as early as November 2006 at least through
January 2007 [52]. In the underlying model of RVFV epidemi-
ology in the RVF predictive system, the initial appearance and
transmission of RVFV originates in transovarially RVFV-infected
Aedes species mosquitoes emerging and surviving in large numbers
following periods of anomalously heavy and sustained rainfall and
vegetation development [26]. These mosquitoes rapidly begin
infecting the primary amplifying hosts, domestic cattle, sheep, and
goats. These reservoirs of RVFV replication provide virus for
further incidental transmission to humans and other animals via
secondary RVFV mosquito vectors, mainly Culex species. Al-
though not conclusive, our findings suggest that the appearance of
RVF-positive sera in the sampled wild ungulate species lag behind
the predicted initiation of the RVF outbreak. As discussed earlier,
serosurveys of some wild ungulates in November 2006 were more
indicative of inter-epizootic levels of RVF-positive samples. Under
the RVFV epidemiological model described in previous studies
where the RVF risk assessment model was developed, RVF-
positive sera in wildlife are not expected to appear until human
cases are observed. Human RVF cases were not observed until
December 2006 [31,32], and in a pattern suggestive of this
epidemiological model, the January 2007 serosamples of wild
animals described in the present study showed greater presence of
RVF than any 2006 samples, though the spatial-temporal
distributions of wild ungulate samples were limited as detailed
above. Future longitudinal surveys involving both livestock and
wild ungulate species can build upon this and related studies and
will enable us to better understand the sequence of transmission
events before and during an epizootic.
Despite the limitations of this study, we can conclude that the
comparison of sample locations to the density of map pixels
flagged for RVFV transmission risk (Table 2) did align with the
overall observation that seroprevalence rates among the sampled
wild ungulate species rises with increasing risk of RVF modeled
across the landscape. In addition, this retrospective survey of RVF-
positive sera in wild ungulates and camel does not challenge the
RVF transmission model. For instance, patterns of change in the
presence of RVF-positive sera over time suggest not only that
RVFV transmission activity actually took place during a predicted
outbreak, but that the timing of transmission to wild ungulates
may have been concordant with the RVFV epidemiological model
of secondary transmission. However, given the study limitations
outlined previously, further research is needed to fully understand
the system. Therefore, longitudinal, systematic serological and
virological surveillance of wild mammalian species is recom-
mended to establish baseline inter-epizootic antibody levels in
wildlife, and thus better track changes in wildlife antibody
prevalence with dynamics of modeled RVFV transmission risk
levels throughout enzootic regions. Ideally, parallel long-term sero-
surveillance studies should also be done in domestic livestock for
comparison to changing levels of RVFV transmission risk.
Together, these can be used to improve the RVFV transmission
risk mapping system by testing and calibrating the underlying
epidemiological model.
Sero-surveillance programs should be carried out across a range
of environments throughout enzootic regions, including areas
inside and outside of the modeled potential epizootic area mask,
thus targeting different wildlife species that occupy certain
ecological niches. With time, as we begin to better understand
the potential role of certain wildlife species in the ecology of RVF,
surveillance strategies and sampling efforts can be refined. Future
sero-surveillance should include GPS locations of animals at the
time of sample and all sampled individuals should be permanently
marked. Demographic data should be recorded to better
characterize the age structure across the samples which will limit
how much of a population sample can be rigorously compared
among years. Representative individuals from target species
should also be tracked with GPS transmitters to get better
information on the movement of herds or individuals as RVFV
transmission risk conditions dynamically change over time.
Conclusions
The combination of climate-based spatial and temporal
predictions of RVF risk combined with targeted wildlife and
domestic livestock serological and virological surveillance could
contribute substantially to understanding RVF epidemiology. The
current study retrospectively supports not only mid-2006 predic-
tions of the 2006–2007 RVF outbreak as published by Anyamba
et al. [52], but also the epidemiological sequence of RVFV
transmission on which the RVF predictive model is based. Future
calibration of the RVF transmission risk model will benefit from
structured serosurveys of both domestic and wild ungulates
throughout the RVF endemic region.
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